TAIPEI, June 22, 2026 /PRNewswire/ — AnHorn Medicines today announced that its lead neuroprotective candidate AH-008, being developed for the prevention of chemotherapy-induced peripheral neuropathy (CIPN), has achieved two major regulatory milestones: Investigational New Drug (IND)…
Welcome to the Healthcare Insights Desk at TheUnplanned.in, where we delve deep into the world of health and wellness. Our dedicated team of writers brings you authoritative articles, expert opinions, and insightful analyses on all facets of healthcare.
Discover more from The Unplanned
Subscribe to get the latest posts sent to your email.
